-
Featured
Avivagen: The OxC-beta™ Technology Is A True Game Changer
Life science stocks are gaining an increasing amount of attention with every passing day as the world continues to battle…
Read More » -
Featured
Excellent Safety Data For COVID-19 Drug Candidate Plus $15 Million In Cash Put NanoViricides In The Driver’s Seat
Anti-viral research has become one of the biggest priorities of the healthcare industry across the globe as the world awaits…
Read More » -
Biotech
Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides’ SARS-CoV-2 Therapeutics Program
Shelton, Connecticut — July 8, 2020 — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) a leader in the development of highly…
Read More » -
Biotech
Pressure Bio: The $3.5 Million Order For Hand Sanitizers Could Really Increase The Momentum Of This Stock
Pressure Bio (OTCPK:PBIO) is one of the most promising microcaps that has been covered by us over the past few…
Read More » -
Biotech
$3,500,000 Initial Order for FDA-Registered, Premium Hand Sanitizer Catapults SkinScience Labs, a Pending Accretive Acquisition of Pressure BioSciences, Into the Multi-Billion Dollar Hand Sanitizer Market
SkinScience Labs, Creator of Award-Winning Dr. Denese Skin Care & Anti-Aging Product Lines, Enters Hand Sanitizer Market with Proprietary Formula…
Read More » -
Uncategorized
Pressure Bio: The New CBD-Infused Immune Booster Is A Superior Product In A Fast-Growing Market
Pressure Bio has been one of the few companies that has made the most of the COVID-19 slowdown and gone…
Read More » -
Biotech
NanoViricides: Drug Candidates Show Fantastic Results In Animal Model
In our earlier pieces, we have provided an in-depth coverage of the promising biopharma smallcap NanoViricides Inc. (NYSE American: NNVC)…
Read More » -
Biotech
Pressure BioSciences Announces Launch of FDA-Registered Hand Sanitizer as First Product Developed Through Pending Merger Partners
South Easton, MA, May 14, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the…
Read More » -
Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering
Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) has entered into an agreement with Canaccord Genuity. Cardiol Therapeutics Inc. (TSX: CRDL)…
Read More » -
Aleafia Health Announces $6.4M Positive Adjusted EBITDA, $14.6M Net Revenue in Q1 2020
Aleafia Health reported earnings results for Q1 2020… Read the full article “Aleafia Health Announces $6.4M Positive Adjusted EBITDA, $14.6M…
Read More »
